$93.84 +2.01 (%) Biomarin Pharmaceutical Inc - NASDAQ

Dec. 19, 2014 | 04:00 PM

Partner Headlines

  1. UPDATE: UBS Securities Reiterates On BioMarin Pharmaceutical On Path To Long-Term Upside

    Benzinga | Dec. 11, 2014 | 10:04AM EST
  2. FDA Grants BioMarin Orphan Drug Designation for NAGLU Fusion Protein, BMN 250, for the Treatment of MPS IIIB

    Benzinga | Dec. 10, 2014 | 08:05AM EST
  3. BioMarin Will Report Breadth of Innovative Development Pipeline at Analyst, Investor Day

    Benzinga | Dec. 9, 2014 | 08:05AM EST
  4. Benzinga's M&A Chatter for Monday November 24, 2014

    Benzinga | Nov. 24, 2014 | 20:20PM EST
  5. BioMarin buying Prosensa

    IBD | Nov. 24, 2014 | 18:43PM EST
  6. Trio Of Major Deals Disclosed

    IBD | Nov. 24, 2014 | 18:42PM EST
  7. Mid-Afternoon Market Update: Trina Solar Drops After Quarterly Results; Tetraphase Pharmaceuticals Shares Spike Higher

    Benzinga | Nov. 24, 2014 | 15:26PM EST
  8. Mid-Day Market Update: Dow Edges Lower; Platinum Underwriters Shares Jump On Acquisition News

    Benzinga | Nov. 24, 2014 | 13:55PM EST
  9. Mid-Morning Market Update: Markets Open Higher; BioMarin To Acquire Prosensa For $17.75/Share

    Benzinga | Nov. 24, 2014 | 11:54AM EST
  10. Benzinga's Volume Movers

    Benzinga | Nov. 24, 2014 | 10:28AM EST
  11. BioMarin Buying Prosensa, Backing Up Troubled Drug

    IBD | Nov. 24, 2014 | 10:22AM EST
  12. Stocks Hitting 52-Week Highs

    Benzinga | Nov. 24, 2014 | 10:18AM EST
  13. Morning Market Movers

    Benzinga | Nov. 24, 2014 | 09:46AM EST
  14. Stock Futures Trending Higher; Kate Spade Bags An Upgrade

    IBD | Nov. 24, 2014 | 09:19AM EST
  15. BioMarin Pharmaceuticals To Acquire Prosensa

    Benzinga | Nov. 24, 2014 | 09:06AM EST
  16. Benzinga's Top #PreMarket Gainers

    Benzinga | Nov. 24, 2014 | 08:10AM EST
  17. US Stock Futures Up Ahead Of Economic Data

    Benzinga | Nov. 24, 2014 | 07:20AM EST
  18. Stocks Hitting 52-Week Highs

    Benzinga | Nov. 10, 2014 | 10:17AM EST
  19. Benzinga's Top Upgrades

    Benzinga | Nov. 10, 2014 | 09:17AM EST
  20. Benzinga's M&A Chatter for Tuesday October 21, 2014

    Benzinga | Oct. 21, 2014 | 20:11PM EST
  21. BioMarin Weathers The Storm

    Benzinga | Aug. 6, 2014 | 16:02PM EST
  22. 4 Top-Rated Drugmakers Beat Q2 Earnings Estimates

    IBD | Aug. 5, 2014 | 18:30PM EST
  23. Biogen Hemophilia Drugs Launch Into The Unknown

    IBD | Jun. 30, 2014 | 17:00PM EST
  24. UPDATE: Credit Suisse Upgrades BioMarin Pharmaceutical

    Benzinga | Jun. 9, 2014 | 09:41AM EST
  25. Benzinga's Top Upgrades

    Benzinga | Jun. 9, 2014 | 07:52AM EST
  26. BioMarin, Medivation Buck Biotech Short Interest Trend (BIIB, BMRN, MDVN)

    Benzinga | Mar. 12, 2014 | 10:01AM EST
  27. Amgen, BioMarin Lead Biotech Short Interest Trend (AMGN, BIIB, BMRN)

    Benzinga | Feb. 27, 2014 | 12:26PM EST
  28. Top Trending Tickers On StockTwits For February 18

    Benzinga | Feb. 18, 2014 | 10:22AM EST
  29. BioMarin Bucks Biotech Short Interest Trend (BIIB, BMRN, MDVN)

    Benzinga | Feb. 13, 2014 | 10:18AM EST
  30. You Can No Longer Ignore Biotech

    GuruFocus | Feb. 7, 2014 | 17:32PM EST
  31. New Year Short Interest Swings In Biotech (BIIB, BMRN, MDVN)

    Benzinga | Jan. 29, 2014 | 11:44AM EST
  32. Celgene, Dendreon Lead Short Interest Trend In Biotechs (BMRN, CELG, DNDN)

    Benzinga | Jan. 11, 2014 | 11:46AM EST
  33. UPDATE: Piper Jaffray Initiates Coverage on BioMarin Pharmaceutical on Expected Attractive Returns

    Benzinga | Nov. 27, 2013 | 11:10AM EST
  34. UPDATE: Piper Jaffray Initiates On BioMarin Pharmaceuticals On BMN-111 Outlook

    Benzinga | Nov. 27, 2013 | 07:50AM EST
  35. BioMarin Wins FDA Panel Vote, Cuts Deal With Myriad

    IBD | Nov. 20, 2013 | 12:11PM EST
  36. Benzinga's Top #PreMarket Gainers

    Benzinga | Nov. 20, 2013 | 08:26AM EST
  37. BioMarin Confirms FDA Panel Recommends Approval of Vimizim for Treatment of Patients with Morquio A Syndrome

    Benzinga | Nov. 19, 2013 | 17:04PM EST
  38. BioMarin Stock Trading Halted Today for FDA Endocrinologic and Metabolic Drugs Advisory Committee

    Benzinga | Nov. 19, 2013 | 07:11AM EST
  39. Gilead Sciences Leads In Rising Short Interest Among Biotechs

    Benzinga | Nov. 12, 2013 | 16:41PM EST
  40. Catalyst Stock Plunge: Ugly In Orphan Drug Land

    YCharts | Nov. 7, 2013 | 12:54PM EST
  41. BioMarin Initiates Phase 3 BMN 673 Trial for Metastatic gBRCA Breast Cancer

    Benzinga | Oct. 31, 2013 | 05:58AM EST
  42. Short Sellers Retreat From Biogen Idec, Move On Pharmacyclics (BIIB, BMRN, PCYC)

    Benzinga | Oct. 25, 2013 | 15:36PM EST
  43. US Oncology, Biomarin Announce Collaboration to Launch PARP Inhibitor Phase III Study in BRCA Metastatic Breast Cancer Patients

    Benzinga | Oct. 24, 2013 | 10:05AM EST
  44. Roche

    IBD | Oct. 23, 2013 | 18:47PM EST
  45. BioMarin Announces 5 Poster Presentations on BMN 673 at AACR-NCI-EORTC International Conference

    Benzinga | Oct. 20, 2013 | 17:01PM EST
  46. Short Sellers Move On Amgen, Vertex (AMGN, PCYC, VRTX)

    Benzinga | Oct. 11, 2013 | 14:33PM EST
  47. Orphan Drugs: No (Payer) News Is Good News

    YCharts | Oct. 9, 2013 | 14:08PM EST
  48. BioMarin Presents Positive Phase 1/2 Data on BMN 673 in Breast Cancer at ECC 2013

    Benzinga | Sep. 29, 2013 | 10:46AM EST
  49. BioMarin, Celgene Lead Trend in Biotech Short Interest (BRMN, CELG, REGN)

    Benzinga | Sep. 25, 2013 | 12:52PM EST
  50. Market Primer: Friday, September 20: US Markets Fall As Investors Re-Evaluate

    Benzinga | Sep. 20, 2013 | 06:45AM EST
Trading Center